论文部分内容阅读
目的观察接受赫赛汀(Herceptin)联合异长春花碱(Vinorelbine,NVB)等药物治疗Her-2过度表达的转移性乳腺癌的疗效和毒副反应。方法20例予赫赛汀(Herceptin)的初始剂量为4mg/kg,以后每周1次,剂量为2mg/kg,至少6周。异长春花碱(NVB)25mg/m2,静脉点滴15min,d1,5;顺铂(DDP)20mg/m2,d1～3,静脉点滴;5-氟尿嘧啶(5-Fu)1.0g/d持续静脉点滴6～12h,d1～3。每21d为1周期。结果总有效率为70%(14/20),其中CR6例(30.0%),PR8例(40%)。中位生存期为14个月。主要毒性为Ⅲ～Ⅳ度粒细胞减少及继发性发热;仅1例观察到II度心脏毒性。结论Herceptin联合化疗作为Her-2过度表达的转移性乳腺癌的解救方案疗效显著,安全可靠。
Objective To observe the curative effect and toxicity of Herceptin combined with Vinorelbine (NVB) in the treatment of Her-2 overexpressed metastatic breast cancer. Methods The initial dose of Herceptin in 20 patients was 4 mg / kg and then once a week at a dose of 2 mg / kg for at least 6 weeks. Vincristine (NVB) 25mg / m2, intravenous drip 15min, d1,5; DDP 20mg / m2, d1 ~ 3, intravenous drip; 5-fluorouracil (5-Fu) 6 ~ 12h, d1 ~ 3. Every 21d for a period. Results The total effective rate was 70% (14/20), including CR6 (30.0%) and PR8 (40%). The median survival was 14 months. The main toxicity was grade Ⅲ ~ Ⅳ neutropenia and secondary fever; only 1 case observed degree II cardiotoxicity. Conclusion Herceptin combined with chemotherapy is a safe, reliable and safe therapeutic solution for Her-2 overexpression in metastatic breast cancer.